News Center
Featured
ACELYRIN, INC. Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Add...
ACELYRIN, INC., a late- stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced the closing of its previously announced upsized initial public offering
Izokibep - Preclinical development and first-in-human study of a novel IL-17A neutralizing Affibody molecule in patients with plaque psoriasis
Publication
Izokibep - Preclinical development and first-in-human study of a novel IL-17A neutralizing Affibody molecule in patients with plaque psoriasis
Read more Izokibep for the treatment of moderate-to-severe plaque psoriasis - a phase II, randomized, placebo-controlled, double-blind, dose-finding multicentre study including long-term treatment
Publication
Izokibep for the treatment of moderate-to-severe plaque psoriasis - a phase II, randomized, placebo-controlled, double-blind, dose-finding multicentre study including long-term treatment
Read more ACELYRIN, INC. Announces Top-Line Results from Placebo-Controlled Clinical Trial of Izokibep for Moderate-to-Severe Hidradenitis Suppurativa
Press Release
ACELYRIN, INC. Announces Top-Line Results from Placebo-Controlled Clinical Trial of Izokibep for Moderate-to-Severe Hidradenitis Suppurativa
Read more ACELYRIN, INC. to Present at the Morgan Stanley 21st Annual Global Healthcare Conference
Press Release
ACELYRIN, INC. to Present at the Morgan Stanley 21st Annual Global Healthcare Conference
Read more ACELYRIN, INC. Reports Second Quarter 2023 Financial Results and Recent Highlights
Press Release
ACELYRIN, INC. Reports Second Quarter 2023 Financial Results and Recent Highlights
Read more ACELYRIN, INC. to Present Second Quarter 2023 Financial Results and Corporate Update on August 14, 2023
Press Release
ACELYRIN, INC. to Present Second Quarter 2023 Financial Results and Corporate Update on August 14, 2023
Read more ACELYRIN, INC. Reports First Quarter 2023 Financial Results And Recent Highlights
Press Release
ACELYRIN, INC. Reports First Quarter 2023 Financial Results And Recent Highlights
Read more ACELYRIN, INC. Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Press Release
ACELYRIN, INC. Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Read more